Applied AI Association of Greater Washington

• Founder of Founders Space
• Top Silicon Valley Startup Expert
• Bestselling Author of Make Elephants Fly
• Widely known as Silicon Valley’s “Godfather of Startups”

Adam Vincent has over two decades of hands-on experience in the cyber security and technology sectors, wearing multiple hats as a practitioner, entrepreneur, and business leader. He is the visionary behind Bricklayer AI, a state-of-the-art generative AI platform tailored for cybersecurity organizations.

A trusted figure in the defense and tech communities, Adam currently holds the position of Senior Commercialization Advisor to Defense Advanced Research Programs Agency (DARPA). Additionally, he lends his expertise as an advisor to several forward-thinking companies and non-profit organizations.

His career includes founding ThreatConnect Inc., a frontrunner in the cybersecurity SaaS space, where he led as CEO through its successful acquisition by Providence Strategic Growth (PSG) in 2019. A seasoned dealmaker, Adam has orchestrated the raising of tens of millions of dollars in funding and possesses a wealth of experience in both the acquisition and sale of businesses.

Adam’s academic achievements include an MS in Computer Science, complemented by a graduate certification in Computer Security and Information Assurance from George Washington University.

Ken Huang is a prolific author and renowned expert in AI and Web3, with numerous published books spanning business and technical guides as well as cutting-edge research. He is a Research Fellow and Co-Chair of the AI Safety Working Groups at the Cloud Security Alliance, Co-Chair of the OWASP AIVSS project, and Co-Chair of the AI STR Working Group at the World Digital Technology Academy. He is also an Adjunct Professor at the University of San Francisco, where he teaches a graduate course on Generative AI for Data Security.

Huang serves as CEO and Chief AI Officer (CAIO) of DistributedApps.ai, a firm specializing in generative AI-related training and consulting. His technical leadership is further reflected in his role as a core contributor to OWASP’s Top 10 Risks for LLM Applications and his participation in the NIST Generative AI Public Working Group.

Key Books:

– Agentic AI: Theories and Practices – Springer, July 2025

– LLM Design Patterns – Packt, May 2025

– Beyond AI: ChatGPT, Web3, and the Business Landscape of Tomorrow -Springer, 2023

– Generative AI Security: Theories and Practices -Springer, 2024)

– Practical Guide for AI Engineers (Volumes 1 and 2 by DistributedApps.ai, 2024)

– The Handbook for Chief AI Officers: Leading the AI Revolution in Business -DistributedApps.ai, 2024

– Web3: Blockchain, the New Economy, and the Self-Sovereign Internet – Cambridge University Press, 2024)

– Web3 Applications Security and New Security Landscape: Theories and Practices -Springer, 2024

– Blockchain and Web3: Building the Cryptocurrency, Privacy, and Security Foundations of the Metaverse (Wiley, 2023)

A globally sought-after speaker, Ken has presented at events hosted by RSA, OWASP, ISC2, Davos WEF, ACM, IEEE, Consensus, the CSA AI Summit, the Depository Trust & Clearing Corporation, and the World Bank. He is also a member of the OpenAI Forum, contributing to global dialogue on secure and responsible AI development.

Explore Ken’s books on Amazon: [https://www.amazon.com/author/kenhuang](https://www.amazon.com/author/kenhuang)

Hubin Jiang is a highly successful serial entrepreneur and award-winning technologist with over three decades of experience founding and growing businesses—often from the ground up without outside financing. As both CEO and hands-on innovator, he has led ventures in critical sectors including COTS software, IT and engineering services, and SaaS. His work spans artificial intelligence, enterprise and records management, social networking, and e-commerce, where he has architected and built cutting-edge systems that solve large-scale, real-world problems. Hubin’s enterprises have earned recognition on the Inc. 5000, Deloitte Technology Fast 500, and Smart CEO 100, and he is also known for turning around struggling businesses through bold, innovation-driven strategies.

Dedicated to fostering the next generation of innovators, Hubin actively mentors young entrepreneurs and supports education programs. As a business mentor for the Entrepreneur Mentoring Program, a partnership between Inc. Magazine and the Clinton Foundation, he was recognized as a success story in the foundation’s yearbook.

Hubin’s journey began in 1987 while pursuing his PhD at the University of Maryland, College Park, where he developed an Adaptive Neural Architecture for Perceptual Object Recognition. This groundbreaking work earned him an Inventors and Inventions Award in 1990, and laid the foundation for a lifelong focus on inference engines, neural networks, natural language processing, machine learning systems, and computer vision. Driven by his entrepreneurial aspirations, he left his PhD Program to dedicate himself fully to innovative undertakings. His contributions to AI and his business achievements underscore a career defined by innovation, resilience, and community impact.

An internationally renowned strategy and innovation expert. The founder and president of the International Applied Science and Technology Institute, the founder and president of the Washon MedData. Mr. Bo is a director of the Overseas Entrepreneurs Alliance of the China Association for Science and Technology and an expert of the China Association for Science and Technology. Co-director of the editorial board of Tsinghua University Press’ Science and Technology Innovation Series and the author of “Technology and Innovation Change the World,”which won 2024 one of the best books in the Press and the author of “AI and Big Data reshape the World” and won the award Data Science and Technology Communication and Promotion Award, Editor-in-Chief of “Digital Infrastructure: Opening a New Era of Digital Economy”. Mr. Bo has more than 20 years of high-tech system development, management and operation experience. He won the Innovation Award of the United Nations Industrial Development Shanghai Innovation Center, the first IHETT digital technology leader TOP10, Huashu Tech for Good, Energy Award, and a member of the Expert Committee of the United Nations Industrial Development Shanghai Intelligent Manufacturing Center. Possess Chinese financial qualifications.

Professor Zhang received his Ph.D. in Computer Science from the McCormick School of Engineering at Northwestern University in 2013.

Dr. Zhang worked as an assistant professor of information and decision science at University of Illinois, Chicago from 2013 to 2015, prior to moving to the Smith School. His research focuses on applying scalable machine learning, natural language processing, and social network analysis techniques on big data problems in business and healthcare. His work has been published in the business journals and computer science conferences. He has presented papers at the INFORMS conference, ICIS conference, and other CS conferences. He teaches Python program in the undergraduate program and big data analytics in the graduate program.

Xuyang Song, Ph.D., MBA, has over 15 years of experience in global

drug development, spanning from drug discovery to drug approval

for both large and small molecules in the fields of oncology,

autoimmune diseases, and other disease areas. He has

participated in multiple INDs, BLAs, and several pivotal clinical

studies, successfully obtaining approvals from global regulatory

agencies and contributing to the successful market launch of two

innovative drugs, IMFINZI® and Imjudo®. He is particularly skilled

in AI and model-informed drug development, applying advanced AI and quantitative methods

to guide decision-making across all stages of the drug development process.

Currently, Dr. Xuyang Song serves as the Global Head of Clinical Pharmacology and Drug

Metabolism and Pharmacokinetics (DMPK) at Adlai Nortye Ltd. (NSDAQ: ANL), where he

oversees the clinical pharmacology and DMPK work across all stages of the company’s pipeline

and leading cross-functional teams to drive the product pipeline forward. He previously held

the position of Director of Clinical Pharmacology and Quantitative Pharmacology at

AstraZeneca, leading a group of experienced clinical pharmacology scientists and

pharmacometricians supporting non-clinical through to late-stage/life cycle management

across multiple product pipelines. Prior to joining AstraZeneca, he worked as a research fellow

at the US Food and Drug Administration (FDA).

Dr. Song has published over 40 papers and abstracts in renowned international journals and

conferences and his research has been cited more than 700 times. Furthermore, he is actively

involved in industry organizations and academic exchanges. He currently serves as the

Secretary-General of the Executive Team of the Chinese Biopharmaceutical Association (CBA),

Chair of the Early Development & Drug Safety Community at the American Society for Clinical

Pharmacology and Therapeutics (ASCPT), and a committee member of the International

Innovative Drug Regulatory Committee of the China Pharmaceutical Innovation and Research

Development Association (PhIRDA) and an invited lecturer for Chinese Course on Drug

Development and Regulatory Sciences (CCDRS) at Peking University Clinical Research Institute.

Dr. Xuyang Song completed his undergraduate education at Shenyang Pharmaceutical

University. He subsequently received his Ph.D. in Pharmaceutical Science, a Master’s degree in

Biostatistics from the University of Florida, and an MBA from the University of Cambridge.